

OCT 30 2008

PAGE 1/6 \* RCVD AT 10/30/2008 10:34:07 PM [Eastern Daylight Time] \* SVR:USPTO-EFXXRF-5/31 \* DNS:2738300 \* CSID:2158511420 \* DURATION (mm:ss):01:16

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Gerard M. Nolan : Attorney Docket No. 03-40062-US-1  
Serial No.: 10/549,961 : Examiner: Fay, Z.  
Filed: September 16, 2005 : Group Art Unit: 1612  
For: METHOD AND COMPOSITION FOR PREVENTING, REDUCING AND  
REVERSING OCULAR ISCHEMIC NEURONAL DAMAGE

---

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO OFFICE ACTION DATED SEPTEMBER 30, 2008**

Sir:

This paper is being filed in response to the Office Action dated September 30, 2008 (Paper No./Mail Date 20080930) (herein referred to as "the Office Action" or "this Office Action") from the Patent Office. In the Office Action, the Examiner has imposed a requirement to elect one of the three groups of inventions for further examination of the above application. Applicant hereby provisionally elects with traverse to further prosecute Group II claims (claims 7-16) and species, Stargardt disease.

This response is timely filed. To the extent any extension is deemed to be necessary, please consider this paper a request for a petition for extension of time. The Commissioner is hereby authorized to charge any fees, which may be required by this paper, to Deposit Account No. 18-0586.